Bayer Healthcare Pharmaceuticals Inc.
$58.0M 146,928 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Biogen, Inc.
Biogen, Inc. reported $59,876,240.47 across General Payments, Research, and Ownership to 36,001 physicians and teaching hospitals across 36,731 transactions.
- $59.9M Top 10% payer
- All-tracks total
- 36,731 Top 10% volume
- Transactions
- 36,001 Top 10% reach
- Recipients
- −$3.5M
- General Payments vs PY2023
Biogen, Inc. reported $59,876,240.47 across all CMS Open Payments tracks (General + Research + Ownership) to 36,001 physicians and teaching hospitals in Program Year 2024 - ranking #42 of 1,925 reporting manufacturers (0.4% of the all-tracks industry total); General Payments alone were $9,178,878.49, averaging $1.7K per recipient.
How Biogen, Inc.'s $59.9M all-tracks total breaks down
Biogen, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
98/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer biogen-inc Biogen, Inc.
$59.9M · #42/1,925 · 0.4% industry · PY2024
- TOT $59.9M
- RANK #42
- SHARE 0.4%
- TXN 36,731
- RCP 36,001
- CAT 7
- GEN $9.2M
- ΔGEN −$3.5M
- TOP1 36.6%
- PY 2024
Volume peers
Nearest volume peer: Bayer Healthcare Pharmaceuticals Inc. ($58.0M)
Biogen, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Biogen, Inc.'s CMS-reported General Payments decreased by $3.5M (−27.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BIOGEN, INC.PY2023: BIOGEN, INC.PY2024: Biogen, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $12,677,569.22
- PY2024
- $9,178,878.49
What the Data Shows for Biogen, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Biogen, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 7 general-payment categories charted below, "Royalty or License" is the largest at $3.6M across 17 transactions, 39.1% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 7 types of general payments, Biogen, Inc.'s largest category was "Royalty or License" at $3.6M - 39.1% of General Payments.
Biogen, Inc. reports 7 general-payment categories - the top three are Royalty or License (39.1%), Compensation for Services Other Than Consulting (22.5%), and Consulting Fee (22.0%). The remaining 4 categories make up 16.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Biogen, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $3.6M | 17 | 39.1% |
| Compensation for Services Other Than Consulting | $2.1M | 734 | 22.5% |
| Consulting Fee | $2.0M | 799 | 22.0% |
| Food and Beverage | $829.9K | 33,619 | 9.0% |
| Grant | $537.9K | 45 | 5.9% |
| Travel and Lodging | $137.1K | 628 | 1.5% |
| Education | $8.3K | 159 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $4,274,695.19 (46.6%) of $9,178,878.49 in this company's General Payments records across 12,006 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Biogen, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Ut Md Anderson Cancer Center
$3,361,793.00 across 4 reported transactions
- 2
Stephen Sherwin
$367,437.19 across 9 reported transactions
- 3
Strong Memorial Hospital
$286,715.00 across 3 reported transactions
- 4
June Halper
$150,000.00 across 1 reported transactions
- 5
Dana-Farber Cancer Institute
$108,750.00 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Biogen, Inc. ranks #42 of 1,925 by total payments (top 2% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #900 of 1,838 by HHI (top 49% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Clinical Laserthermia Systems Americas Inc. : $1.7K total payments, HHI 1414
- ABK Biomedical USA, Inc. : $6.6K total payments, HHI 1409
- Cadwell Industries, INC : $39.8K total payments, HHI 1407
- Carestream Dental, LLC : $175.9K total payments, HHI 1402
- Daxor Corporation : $270.6K total payments, HHI 1400
- US Retina LLC : $355.0K total payments, HHI 1391
- Biogen, Inc. (this company) : $9.2M total payments, HHI 1387
- Helsinn Therapeutics (U.S.), Inc. : $24.3K total payments, HHI 1382
- Fusion Orthopedics, LLC. : $5.0K total payments, HHI 1377
- NuSmile, Ltd. : $310.2K total payments, HHI 1377
- Orpyx Medical Technologies US Inc. : $205.97 total payments, HHI 1372
- Otsuka Pharmaceutical Co., Ltd. : $357.1K total payments, HHI 1372
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Biogen, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Biogen, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Biogen, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Advanced Accelerator Applications
$63.9M 167 recipients
Compare payment profiles
Lilly USA, LLC
$54.3M 544,473 recipients
Compare payment profiles
Teva Pharmaceuticals USA, Inc.
$67.4M 141,158 recipients
Compare payment profiles
US Retina LLC
$50.8M 8 recipients
Compare payment profiles
Smith+Nephew, Inc.
$50.5M 71,450 recipients
Compare payment profiles
Put this to use
Biogen, Inc. ranks #42 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See where Biogen, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just Biogen, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.